Across TCGA pan-cancer cohorts, BMP4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BMP4 data layer compared with 21 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BMP4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BMP4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
HNSC and LSCC are the cancer types where BMP4 mass-spec protein most reproducibly stratifies survival.